Innovative approaches needed to overcome health system barriers in malaria vaccination

Four boys with a rare and of­ten se­vere ge­net­ic mus­cle dis­ease died in 2020 and 2021 af­ter re­ceiv­ing a one-time gene ther­a­py from Astel­las Phar­ma,

Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion vice chair John Crow­ley will be­come the next CEO of the in­dus­try’s ad­vo­ca­cy and lob­by­ing or­ga­ni­za­tion on March 4, pick­ing an in­sid­er

The Phase III FURVENT trial of furmonertinib to treat first-line NSCLC with EGFR exon 20 insertion mutations is enrolling subjects. Credit: create jobs 51 /